Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abivax SA - American Depositary Shares (NQ:ABVX)

117.10 +0.30 (+0.26%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abivax SA - American Depositary Shares

< Previous 1 2 3 4 Next >
Top movers in Monday's pre-market session ↗
Via Chartmill
ABVX Soars Pre-Market On Reports Of $17.5 Billion Eli Lilly Takeover Interest ↗
Via Stocktwits
News headline image
Abivax Provides 2026 Corporate Outlook
From Abivax
Via GlobeNewswire
News headline image
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Could This Potential Move Boost Eli Lilly's Prospects? ↗
The stock already looks unstoppable, and this move won't hurt its momentum. 
Via The Motley Fool
News headline image
The 2025 Growth Postgame: Analyzing the AI Supercycle and Preparing for the 2026 'Agentic' Pivot
As the final trading days of 2025 wind down, the global investment community has entered a period of intense reflection. This year’s market was defined by a breathtaking "tale of two halves," where... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
How Abivax Went From Biotech Nobody To M&A Bullseye After A Single Blockbuster Readout This Year ↗
A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Head Into Christmas Eve With Caution: Why ASTS, DVAX, ABVX, PATH, GOOGL Are On Traders' Radar Today ↗
Markets are moving from a record-setting close into a thin, holiday-shortened Christmas Eve session. 
Via Stocktwits
Topics ETFs Stocks
News headline image
The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave
As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results... 
Via MarketMinute
Topics Intellectual Property
News headline image
Why Abivax Stock Was on Fire Today ↗
Investors were excited about the possibility of a buyout with a high price tag. 
Via The Motley Fool
News headline image
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Abivax to be Added to Nasdaq Biotechnology Index
From Abivax
Via GlobeNewswire
News headline image
The Great Rotation: Small-Cap Growth Surges as Investors Ditch Defensive Safety for Post-Fed Gains
The financial markets are witnessing a historic "Great Rotation" this December, as the era of defensive posturing and mega-cap concentration appears to be giving way to a broad-based growth rally.... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
From Abivax
Via GlobeNewswire
News headline image
Abivax Presents Third Quarter 2025 Financial Results
From Abivax
Via GlobeNewswire
News headline image
2 Under-the-Radar Stocks That Have Soared This Year ↗
These companies are worth your attention. 
Via The Motley Fool
News headline image
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗
A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters. 
Via The Motley Fool
News headline image
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗
Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down. 
Via The Motley Fool
News headline image
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗
A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
6 Healthcare Stocks With Strong Upward Momentum ↗
 
Via Benzinga
News headline image
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗
A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗
This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗
A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks. 
Via The Motley Fool
News headline image
This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
From Abivax
Via GlobeNewswire
News headline image
Tilray Brands Posts Upbeat Results, Joins Byrna Technologies, Delta Air Lines And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
AMD To Rally More Than 47%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Why Is Abivax Stock Trading Higher On Monday? ↗
Abivax said Phase 3 trials showed obefazimod improved clinical outcomes in ulcerative colitis, meeting key endpoints with no new safety concerns. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.